GO
Loading...

Allergan Inc

More

  • Ackman to CNBC: Support Actavis-Allergan deal   Tuesday, 18 Nov 2014 | 10:27 AM ET
    Ackman to CNBC: Support Actavis-Allergan deal

    CNBC's David Faber reports investor Bill Ackman has told CNBC he will withdraw from the special meeting on December 18th where Actavis shareholders could have voted on new directors.

  • Ackman has the luck of a loser, to the tune of $2.2B Tuesday, 18 Nov 2014 | 7:02 AM ET
    Bill Ackman

    Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • Hedge funds ditch Apple for AbbVie and Alibaba Tuesday, 18 Nov 2014 | 5:29 AM ET
    A couple look at an Apple Inc. iPhone 6 at an Apple store in the China Central Mall in Beijing, China, on Tuesday, Nov. 11, 2014.

    Hedge funds flocked to Apple ahead of launch of the iPhone 6, but the company is now the most sold position among some of world's largest funds.

  • A day after shock data showing Japan slipping into recession had rattled financial markets, Japan's Nikkei rose 1.7 percent, erasing about a half of Monday's 3.0 percent fall. Prime Minister Shinzo Abe is expected to announce later in the day that he is calling a snap election, banking on the ruling Liberal Democrat Party trouncing a weak opposition to reaffirm...

  • Tracking the Allergan-Actavis merger   Monday, 17 Nov 2014 | 7:32 PM ET
    Tracking the Allergan-Actavis merger

    Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.

  • Cramer Remix: This stock has begun to turn around Monday, 17 Nov 2014 | 7:08 PM ET
    Jim Cramer on Mad Money.

    Wall Street research was ready to give up, but "Mad Money" host Jim Cramer thinks this could be the start of a major turnaround.

  • Cramer: The lucrative journey of Allergan Monday, 17 Nov 2014 | 6:07 PM ET
    Allergan Actavis

    Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 8.9 percent, and Allergan, up 5.3 percent, gave the S&P 500 its biggest boost after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. "It shows the strength of the overall market that you could have this recession news out of Japan, and yet have the...

  • Stocks little moved; S&P 500 at record-high close Monday, 17 Nov 2014 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks fell Monday after data had Japan unexpectedly falling into a recession.

  • Ackman's win-win   Monday, 17 Nov 2014 | 3:18 PM ET
    Ackman win-win

    Actavis announced it will acquire Allergan for $66 billion. Marc LoPresti of Lopresti Law Group, and Michael Farr of Farr, Miller & Washington, discuss Pershing Square Bill Ackman's actions.

  • Nov 17- Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. Besides the higher price tag, the Actavis deal came with only $400 million in R&D cuts for Allergan, far less than the $900 million decrease...

  • *Brent falls toward $78 as Japanese growth stalls. NEW YORK, Nov 17- Oil prices fell and global equity markets were mixed on Monday after news that Japan unexpectedly slipped into recession in the third quarter renewed concerns about the world economy, but merger activity and comment about European stimulus capped declines. Brent oil initially fell more than $1...

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 10.2 percent, and Allergan, up 5.1 percent, led gains on the S&P 500 after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. The largest percentage gainer on the S&P 500 was Baker Hughes, while the largest decliner was Halliburton, down 10.1 percent.

  • NEW YORK, Nov 17- Actavis will issue around US $27.5 bn of new debt to finance its US $66 bn acquisition of Botox-maker Allergan, but about half of it will be short-dated to help the company keep its investment-grade ratings. Both Moody's and Fitch said they would not downgrade Actavis to junk despite the increased debt, believing strong cash flow will enable it to...

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...

  • Midday movers: Allergan, CarMax, CBS & more Monday, 17 Nov 2014 | 1:03 PM ET
    NYSE New York Stock Exchange traders markets

    Some of Monday's midday movers:

  • NEW YORK, Nov 17- Hedge fund Omega Advisors expects to see the U.S. stock market's bull run continue into next year, fueled by steady economic growth and a corporate takeover boom. "My expectation is for the Standard& Poor's 500 to gain 7 percent to 9 percent in 2015," Steven Einhorn, Omega's vice chairman said on Monday. Omega, founded by Leon Cooperman two decades ago...

  • Hedge fund winners in Allergan deal   Monday, 17 Nov 2014 | 12:33 PM ET
    Hedge fund winners in Allergan deal

    Actavis is buying Allergan for $66 billion. CNBC's Kate Kelly provides insight to speculation surrounding the benefit of the deal to Pershing Square's Bill Ackman.

  • *Baker Hughes rallies, Halliburton tumbles after deal. The M&A news partly offset the declines as Allergan agreed to be bought by Actavis while Halliburton said it would buy Baker Hughes. Allergan and Baker Hughes were the top point gainers on the S&P 500..